DGAP-Adhoc: Carl Zeiss Meditec achieves EBIT margin of 18.1% in fiscal year 2018/19
DGAP-Ad-hoc: Carl Zeiss Meditec AG / Key word(s): Annual Results
Carl Zeiss Meditec achieves EBIT margin of 18.1% in fiscal year 2018/19
23-Oct-2019 / 13:55 CET/CEST
Update of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
|
Carl Zeiss Meditec achieves EBIT margin of 18.1% in fiscal year 2018/19
Jena, October 23, 2019
As already announced on October 2, 2019, Carl Zeiss Meditec AG (ISIN: DE0005313704) has achieved revenue of EUR 1,459 million in fiscal year 2018/19 (past year: EUR 1,280.9 million) and has significantly expanded EBIT[1] margin[2], exceeding the initial forecast of 15.0% to 17.5%. Based on today's new assessment, EBIT for fiscal year 2018/19 amounted to approx. EUR 264 million (past year: EUR 197.1 million), leading to an EBIT margin of 18.1%.
Upon publication of preliminary results on October 2, 2019, the company had anticipated a still higher EBIT margin for fiscal year 2018/19.
The shortfall was caused by higher operating expenses in the fourth quarter of fiscal year 2018/19, in part driven by the already announced higher investments in the fields of Surgical Ophthalmology and Digitalization.
Final results for fiscal year 2018/19 will be provided on December 6, 2019. |
|
Contact for investors and press
Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Tel.: +49 3641 220-116
E-Mail: [email protected]
[1] Earnings before interest and taxes (also operating profit, EBIT) refers to a key earnings figure within the Carl Zeiss Meditec Group and is calculated in accordance with IFRS standards (see Annual Report 2017/18, p. 76 for reconciliation). [2] Calculation: EBIT margin = EBIT / revenue (in %) (see Annual Report 2017/18, p. 76).
23-Oct-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
|
Language: |
English |
Company: |
Carl Zeiss Meditec AG |
|
Göschwitzer Str. 51-52 |
|
07745 Jena, Germany |
|
Germany |
Phone: |
+49 (0)3641 220-0 |
Fax: |
+49 (0)3641 220-112 |
E-mail: |
[email protected] |
Internet: |
www.zeiss.de/meditec-ag/ir |
ISIN: |
DE0005313704 |
WKN: |
531370 |
Indices: |
MDAX, TecDAX |
Listed: |
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: |
894865 |
|
End of Announcement |
DGAP News Service |
894865 23-Oct-2019 CET/CEST
Die wichtigsten Finanzdaten auf einen Blick
|
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023e |
Umsatzerlöse1 |
1.189,90 |
1.280,86 |
1.459,32 |
1.335,45 |
1.646,79 |
1.902,84 |
2.089,30 |
EBITDA1,2 |
205,07 |
228,41 |
313,03 |
237,98 |
435,20 |
466,65 |
422,19 |
EBITDA-Marge3 |
17,23 |
17,83 |
21,45 |
17,82 |
26,43 |
24,52 |
|
EBIT1,4 |
180,83 |
197,13 |
264,66 |
177,55 |
373,61 |
396,88 |
348,12 |
EBIT-Marge5 |
15,20 |
15,39 |
18,14 |
13,30 |
22,69 |
20,86 |
16,66 |
Jahresüberschuss1 |
135,78 |
126,23 |
160,58 |
123,42 |
237,52 |
295,91 |
292,01 |
Netto-Marge6 |
11,41 |
9,86 |
11,00 |
9,24 |
14,42 |
15,55 |
13,98 |
Cashflow1,7 |
37,73 |
187,21 |
219,63 |
178,53 |
362,66 |
188,20 |
250,86 |
Ergebnis je Aktie8 |
1,57 |
1,41 |
1,79 |
1,37 |
2,64 |
3,29 |
3,25 |
Dividende8 |
0,55 |
0,55 |
0,65 |
0,50 |
0,90 |
1,10 |
0,42 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2023 - Kostenfrei herunterladen.
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: PricewaterhouseCoopers
|
INVESTOR-INFORMATIONEN |
©boersengefluester.de |
Carl Zeiss Meditec |
WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
531370 |
97,700 |
Halten |
8.738,34 |
KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
27,52 |
35,03 |
0,79 |
47,89 |
KBV |
KCV |
KUV |
EV/EBITDA |
4,24 |
34,83 |
4,18 |
18,63 |
Dividende '22 in € |
Dividende '23e in € |
Div.-Rendite '23e in % |
Hauptversammlung |
1,10 |
1,10 |
1,13 |
21.03.2024 |
Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
09.02.2024 |
08.05.2024 |
06.08.2024 |
12.12.2023 |
Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
-11,47% |
1,63% |
-1,15% |
-19,82% |
|
|